GlassScriptPhysician profile
Gregory M Metz
NPI 1174797062
$5,539.87
in general payments reported to CMS, 2019-2025
26 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $410 · 2021: $722 · 2022: $894 · 2023: $633 · 2024: $835 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,748.80 |
| Education | $164.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $886.42 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $776.13 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $668.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $453.87 | 2020-2025 | |
| Csl Behring | $409.46 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genentech USA, INC. | $313.00 | 2019-2025 | Xolair |
| Pfizer INC. | $288.78 | 2019-2025 | |
| Pharming Healthcare, INC. | $225.19 | 2021-2025 | Ruconest |
| Kaleo, INC. | $199.75 | 2019-2022 | |
| Alk-Abello, INC | $194.34 | 2019-2024 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Blueprint Medicines Corporation | $192.43 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $190.85 | 2021-2024 | Hyqvia, Takhzyro |
| Amgen INC. | $124.66 | 2021-2025 | Tezspire |
| Optinose US, INC. | $121.70 | 2019-2025 | |
| Genentech, INC. | $81.80 | 2022-2024 | Xolair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $74.60 | 2022-2025 | Orladeyo |
| Abbvie INC. | $71.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $64.49 | 2019-2020 | |
| Shire North American Group INC | $44.12 | 2019 | |
| Grifols USA, LLC | $34.21 | 2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $26.47 | 2025 | Neffy |
| Dermavant Sciences, INC. | $25.39 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $23.61 | 2025 | Nemluvio |
| Aimmune Therapeutics, INC. | $19.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.14 | 2021 | |
| Lilly USA, LLC | $13.67 | 2025 | Ebglyss |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Metz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.